Gilead is researching new treatments to help address the needs of people living with inflammatory and fibrotic diseases, including inflammatory bowel disease, lupus, rheumatoid arthritis, atopic dermatitis and nonalcoholic steatohepatitis. Leveraging our extensive expertise in immunology and network of partnerships, we are advancing a range of early-stage programs to help meet these chronic conditions and the toll they take on patients’ lives.
Vision and Goals
Our goal is to develop effective therapies for treating inflammatory and fibrotic diseases. This is an area of significant unmet need, as many patients have few or no treatment options for their condition or experience symptoms or disease progression.
We believe long-term remission is possible for many of these diseases – and for some, even a cure – despite the challenges they present. We’re leveraging our successes and learnings from HIV and hepatitis and applying them to our research with the hope of bringing effective therapies to as many patients as possible.
Areas of Focus
We have more than 20 active research programs, including five potentially transformative molecules that have advanced to the clinical stage. Our areas of focus include:
Our Scientific Approach
Inflammatory and fibrotic diseases are often characterized by a vicious cycle of tissue damage, immune response and fibrosis (scarring) that leads to organ damage and disease progression over time. Our programs focus on disrupting that cycle through four different methods, which we call our BETR framework:
- Blocking immune activation
- Eliminating pathogenic cells
- Tolerizing immune response
- Restoring function & promote regeneration
Many of our investigational molecules are also being researched as combination therapies.